HIV and inflammatory markers are associated with persistent COVID-19 symptoms.
HIV
biomarker
immunological factors
long COVID
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
25
03
2023
received:
26
12
2022
accepted:
21
04
2023
medline:
31
5
2023
pubmed:
30
5
2023
entrez:
30
5
2023
Statut:
ppublish
Résumé
A proportion of COVID19 survivors may present with long-COVID, which is persistent symptoms lasting four or more weeks post SARS-CoV-2 infection. These symptoms may be mild to severe, and may affect different organ-systems of the body. The main objective of this study was to determine the demographic, clinical and immunological factors associated with long COVID. We conducted a nested case control study, with a total of 94 study participants initially included, and 64 participants matched for age and sex for biomarker analyses. 32/94 (34.1%) of all the participants had long COVID. Respiratory symptoms were the most common (59.5%) followed by the musculoskeletal symptoms (28.1%). HIV was an independent predictor of long COVID (adjusted odds ratio = 2.7; p = .037). In all the 64 matched cases and controls, IFN-β was significantly higher among controls than cases. After stratifying by HIV, IL6 was significantly higher among cases than controls in the HIV- group (2.06 vs. 0.81 pg/mL; p = .02). On the other hand, IFN-β was significantly higher among controls than cases in the HIV+ group (251 vs. 0 pg/mL; p = .01). HIV infection is a risk factor for long COVID, and inflammatory markers associated with long COVID may be slightly different for HIV- and HIV+ individuals.
Sections du résumé
BACKGROUND
A proportion of COVID19 survivors may present with long-COVID, which is persistent symptoms lasting four or more weeks post SARS-CoV-2 infection. These symptoms may be mild to severe, and may affect different organ-systems of the body.
AIMS
The main objective of this study was to determine the demographic, clinical and immunological factors associated with long COVID.
MATERIALS & METHODS
We conducted a nested case control study, with a total of 94 study participants initially included, and 64 participants matched for age and sex for biomarker analyses.
RESULTS
32/94 (34.1%) of all the participants had long COVID. Respiratory symptoms were the most common (59.5%) followed by the musculoskeletal symptoms (28.1%). HIV was an independent predictor of long COVID (adjusted odds ratio = 2.7; p = .037). In all the 64 matched cases and controls, IFN-β was significantly higher among controls than cases. After stratifying by HIV, IL6 was significantly higher among cases than controls in the HIV- group (2.06 vs. 0.81 pg/mL; p = .02). On the other hand, IFN-β was significantly higher among controls than cases in the HIV+ group (251 vs. 0 pg/mL; p = .01).
CONCLUSION
HIV infection is a risk factor for long COVID, and inflammatory markers associated with long COVID may be slightly different for HIV- and HIV+ individuals.
Identifiants
pubmed: 37249281
doi: 10.1002/iid3.859
pmc: PMC10165949
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e859Subventions
Organisme : FIC NIH HHS
ID : K43 TW011095
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA221204
Pays : United States
Informations de copyright
© 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Int J Infect Dis. 2023 Feb;127:106-115
pubmed: 36516914
Ann Am Thorac Soc. 2021 May;18(5):799-806
pubmed: 33433263
PLoS One. 2019 May 13;14(5):e0216787
pubmed: 31083692
Radiology. 2021 Nov;301(2):E383-E395
pubmed: 34374591
J Cell Physiol. 2021 Apr;236(4):2829-2839
pubmed: 32926425
Ann Neurol. 1996 Mar;39(3):285-94
pubmed: 8602746
Cell. 2020 Nov 25;183(5):1340-1353.e16
pubmed: 33096020
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Cells. 2019 Aug 17;8(8):
pubmed: 31426476
Immun Inflamm Dis. 2021 Sep;9(3):1037-1043
pubmed: 34078004
Viruses. 2019 Feb 27;11(3):
pubmed: 30818749
AIDS. 2022 Oct 1;36(12):F7-F16
pubmed: 35866847
Clin Exp Immunol. 2017 Jan;187(1):44-52
pubmed: 27198731
Lancet Respir Med. 2022 Aug;10(8):761-775
pubmed: 35472304
Nat Immunol. 2022 Feb;23(2):194-202
pubmed: 35105985
Front Pharmacol. 2018 Nov 28;9:1368
pubmed: 30555324
Health Sci Rep. 2022 May 23;5(3):e657
pubmed: 35620541
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Infect Dis (Lond). 2021 Oct;53(10):737-754
pubmed: 34024217
Nat Immunol. 2022 Feb;23(2):210-216
pubmed: 35027728
Nat Med. 2022 Aug;28(8):1706-1714
pubmed: 35879616
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Psychoneuroendocrinology. 2020 Aug;118:104689
pubmed: 32479968
Pulmonology. 2021 Jul-Aug;27(4):328-337
pubmed: 33262076